Table 2.
Meta-analysis of AD-associated haplotypes after controlling for APOE genotypes
| Haplotypes | Study # | Beta (RE) | SD (RE) | p-value (RE2) | I 2 | Q | p-value (Q) | Tau 2 |
|---|---|---|---|---|---|---|---|---|
| Haplotypes in the PVRL2 region | ||||||||
| aagtaagacgcacga | 6 | 0.161 | 0.059 | 8.97E−03 | 0.00 | 3.68 | 5.96E−01 | 0.00 |
| GGCCGCgacgTAAT | 6 | 0.059 | 0.070 | 6.97E−02 | 40.12 | 8.35 | 1.38E−01 | 0.01 |
| GGCCGCTGcgTAAT | 5 | −0.098 | 0.096 | 3.66E−01 | 0.00 | 3.68 | 4.51E−01 | 0.00 |
| Haplotypes in the APOC1 region | ||||||||
| tatttcttcgcagagcaa | 6 | 0.635 | 0.193 | 1.72E−08 | 42.43 | 8.69 | 1.22E−01 | 0.08 |
| tGGttcttcgcGCGAATG | 6 | −0.345 | 0.316 | 3.40E−01 | 0.00 | 2.60 | 7.62E−01 | 0.00 |
| Extended haplotypes | ||||||||
|
aagtaagacgcacga cC tatttcttcgcagagcaa (ε4) |
6 | 0.356 | 0.218 | 6.28E−04 | 45.62 | 9.20 | 1.02E−01 | 0.11 |
|
GGCCGCTGTTTAAT cC tatttcttcgcagagcaa (ε4) |
6 | 0.312 | 0.259 | 4.10E−04 | 51.06 | 10.22 | 6.93E−02 | 0.17 |
|
GGCCGCgacgTAAT cC tatttcttcgcagagcaa (ε4) |
4 | 0.570 | 0.120 | 3.14E−06 | 0.00 | 2.73 | 4.35E−01 | 0.00 |
Note: Summary metrics from association results, controlling for APOE-ε4 and APOE-ε2 genotypes obtained from different AD cohort data, were subjected to METASOFT for meta-analysis. A random effects (RE) model based on inverse-variance-weighted effect size was applied to estimate summary-level effect size (Beta) and standard deviation. Han and Eskin’s random effects (RE2) model was applied to estimate the significance level, accounting for possible heterogeneity across populations
AD Alzheimer’s disease, Beta effect size, SE standard deviation, RE random effects model, RE2 Han and Eskin’s random effects model, I2 I-squared heterogeneity statistic, Q Cochrane’s Q-statistic, Tau2 Tau-squared heterogeneity estimator of Der Simonian–Laird